Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
24 Avril 2023 - 10:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of April 2023
Commission File Number: 001-37452
CELYAD ONCOLOGY SA
(Translation of registrants name into English)
Rue Edouard
Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Celyad Oncology SA
On April 24, 2023, Celyad Oncology SA (the Company) issued a press release announcing that it had received a letter (the Bid
Price Notice) on April 19, 2023 from The Nasdaq Stock Market informing the Company that the minimum closing bid price per share of its American Depositary Shares representing ordinary shares (ADSs) was below $1.00
for a period of 30 consecutive business days, and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Price Requirement).
The Bid Price Notice has no immediate effect on the listing of the Companys ADSs on the Nasdaq Global Market. In accordance with Nasdaq Listing Rule
5810(c)(3)(A), the Company has 180 calendar days, or until October 16, 2023, to regain compliance with the Minimum Bid Price Requirement.
A copy of
the Companys press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information contained in this Current
Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Companys Registration Statements on Forms F-3 (File No. 333-248464) and S-8 (File No. 333-220737).
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CELYAD ONCOLOGY SA |
|
|
|
|
Date: April 24, 2023 |
|
|
|
By: |
|
/s/ Georges Rawadi |
|
|
|
|
|
|
Georges Rawadi |
|
|
|
|
|
|
Chief Executive Officer |
Celyad (CE) (USOTC:CLYYF)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Celyad (CE) (USOTC:CLYYF)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024
Real-Time news about Celyad SA (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Celyad Oncology Sa